Cargando…

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

BACKGROUND: In a cross-sectional study we studied the fasting serum DPP-4 enzymatic activity (sDPP-4) and the insulin resistance index (HOMA2-IR) in gliptin naïve patients with type 2 diabetes and in non-alcoholic fatty liver disease (NAFLD) and in healthy controls (CNTRL). METHODS AND FINDINGS: sDP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Firneisz, Gábor, Varga, Tímea, Lengyel, Gabriella, Fehér, János, Ghyczy, Dóra, Wichmann, Barna, Selmeci, László, Tulassay, Zsolt, Rácz, Károly, Somogyi, Anikó
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923594/ https://www.ncbi.nlm.nih.gov/pubmed/20805868 http://dx.doi.org/10.1371/journal.pone.0012226

Ejemplares similares

Rebound increase in circulating dipeptidyl peptidase 4 (DPP4) enzyme activity after acute COVID-19
por: Firneisz, Gábor
Publicado: (2023)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
por: Kinyó, Ágnes, et al.
Publicado: (2021)

Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
por: Chen, Lin, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
por: Nádasdi, Ákos, et al.
Publicado: (2022)

Altered Immune Regulation in Type 1 Diabetes
por: Zóka, András, et al.
Publicado: (2013)

Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
por: Huang, Jie, et al.
Publicado: (2022)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Exercise combined with a probiotics treatment alters the microbiome, but moderately affects signalling pathways in the liver of male APP/PS1 transgenic mice
por: Téglás, Tímea, et al.
Publicado: (2020)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

Increased Proportion of Hematopoietic Stem and Progenitor Cell Population in Cord Blood of Neonates Born to Mothers with Gestational Diabetes Mellitus
por: Hadarits, Orsolya, et al.
Publicado: (2016)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
por: Pinto-Lopes, Pedro, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
por: Roy, Ayan, et al.
Publicado: (2021)

Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease
por: Zhang, Yuanyuan, et al.
Publicado: (2022)

Reduced GLP-1 response to a meal is associated with the CTLA4 rs3087243 G/G genotype
por: Zóka, András, et al.
Publicado: (2019)

Dipeptidyl peptidase‐4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats
por: Younan, Nagat, et al.
Publicado: (2019)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease
por: Yang, Guang, et al.
Publicado: (2016)

SAT-413 Does Dipeptidyl Peptidase-4 Inhibitor Exacerbate Graves’ Disease?
por: Sekizaki, Tomonori, et al.
Publicado: (2020)

Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
por: Jaenisch, Simone E., et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
por: Daza-Arnedo, Rodrigo, et al.
Publicado: (2021)

Aminopeptidase A and dipeptidyl peptidase 4: a pathogenic duo in Alzheimer’s disease?
por: Checler, Frédéric, et al.
Publicado: (2022)

The effect of dipeptidyl peptidase IV on disease-associated microglia phenotypic transformation in epilepsy
por: Zheng, Zhicheng, et al.
Publicado: (2021)

Identification and Potential Clinical Utility of the MTNR1B rs10830963 Core Gene Variant Associated to Endophenotypes in Gestational Diabetes Mellitus
por: Firneisz, Gábor, et al.
Publicado: (2020)

Dipeptidyl Peptidase IV Inhibitor Improves Insulin Resistance and Steatosis in a Refractory Nonalcoholic Fatty Liver Disease Patient: A Case Report
por: Itou, Minoru, et al.
Publicado: (2012)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
por: Ideta, Takayasu, et al.
Publicado: (2015)

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
por: Oh, Ju Hee, et al.
Publicado: (2022)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content
por: Nádasdi, Ákos, et al.
Publicado: (2023)

Health economic evaluation of dipeptidyl peptidase-4 inhibitors
por: Garg, Vishvas
Publicado: (2011)

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose
por: Das, Siddhartha Shankar, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0ar4quu9pqev04q5t34fr5e1t9